(R)-1-(4-(4-(Hydroxymethyl)-1,3,2-dioxaborolan-2-YL)phenyl)guanidine
Star0
Identification
- Generic Name
- (R)-1-(4-(4-(Hydroxymethyl)-1,3,2-dioxaborolan-2-YL)phenyl)guanidine
- DrugBank Accession Number
- DB07077
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 235.047
Monoisotopic: 235.112821795 - Chemical Formula
- C10H14BN3O3
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCoagulation factor XI Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Not Available
- Direct Parent
- Benzene and substituted derivatives
- Alternative Parents
- Dioxaborolanes / Boronic acid esters / Guanidines / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Organic metalloid salts / Primary alcohols / Organopnictogen compounds / Organoboron compounds / Hydrocarbon derivatives
- Substituents
- 1,3,2-dioxaborolane / Alcohol / Aromatic heteromonocyclic compound / Boronic acid derivative / Boronic acid ester / Guanidine / Hydrocarbon derivative / Monocyclic benzene moiety / Organic 1,3-dipolar compound / Organic metalloid salt
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- PTRUIYBNRUNGLM-SECBINFHSA-N
- InChI
- InChI=1S/C10H14BN3O3/c12-10(13)14-8-3-1-7(2-4-8)11-16-6-9(5-15)17-11/h1-4,9,15H,5-6H2,(H4,12,13,14)/t9-/m1/s1
- IUPAC Name
- N''-{4-[(4R)-4-(hydroxymethyl)-1,3,2-dioxaborolan-2-yl]phenyl}guanidine
- SMILES
- NC(N)=NC1=CC=C(C=C1)B1OC[C@@H](CO)O1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 6857692
- PubChem Substance
- 99443548
- ChemSpider
- 5257026
- ZINC
- ZINC000169748493
- PDBe Ligand
- 427
- PDB Entries
- 1zmn
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.765 mg/mL ALOGPS logP 0.15 ALOGPS logP 0.76 Chemaxon logS -2.5 ALOGPS pKa (Strongest Acidic) 14.65 Chemaxon pKa (Strongest Basic) 10.09 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 103.09 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 59.64 m3·mol-1 Chemaxon Polarizability 25.22 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9812 Blood Brain Barrier + 0.9269 Caco-2 permeable - 0.5923 P-glycoprotein substrate Non-substrate 0.7481 P-glycoprotein inhibitor I Non-inhibitor 0.9283 P-glycoprotein inhibitor II Non-inhibitor 0.9156 Renal organic cation transporter Non-inhibitor 0.7574 CYP450 2C9 substrate Non-substrate 0.8023 CYP450 2D6 substrate Non-substrate 0.7734 CYP450 3A4 substrate Non-substrate 0.7502 CYP450 1A2 substrate Non-inhibitor 0.6855 CYP450 2C9 inhibitor Non-inhibitor 0.7959 CYP450 2D6 inhibitor Non-inhibitor 0.8685 CYP450 2C19 inhibitor Non-inhibitor 0.757 CYP450 3A4 inhibitor Non-inhibitor 0.9005 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8827 Ames test AMES toxic 0.5936 Carcinogenicity Non-carcinogens 0.7474 Biodegradation Not ready biodegradable 0.9747 Rat acute toxicity 2.4053 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9407 hERG inhibition (predictor II) Non-inhibitor 0.9357
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCoagulation factor XI
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX.
- Gene Name
- F11
- Uniprot ID
- P03951
- Uniprot Name
- Coagulation factor XI
- Molecular Weight
- 70108.56 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:18 / Updated at June 12, 2020 16:52